Stocks
Avanos Medical Financial Statements (AVNS) |
||||||||||
| Avanos Medicalsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 03.05.2023 | 09.08.2023 | 01.11.2023 | 21.02.2024 | 02.05.2024 | 02.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 191.7 | 169.4 | 171.3 | 173.3 | 166.1 | 680.1 | |||
| Operating Income, bln rub | 2.60 | -2.10 | 1.20 | 22.2 | 7.40 | 28.7 | ||||
| EBITDA, bln rub | ? | 15.2 | 9.90 | 13.1 | 33.7 | 18.8 | 75.5 | |||
| Net profit, bln rub | ? | -0.500 | -68.1 | -3.70 | 10.5 | -0.900 | -62.2 | |||
| OCF, bln rub | ? | -6.80 | -2.60 | 29.1 | 12.7 | -8.00 | 31.2 | |||
| CAPEX, bln rub | ? | 4.00 | 4.00 | 3.90 | 5.90 | 4.10 | 17.9 | |||
| FCF, bln rub | ? | -10.8 | -6.60 | 25.2 | 6.80 | -12.1 | 13.3 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 101.9 | 99.9 | 94.3 | 75.2 | 87.4 | 356.8 | ||||
| Cost of production, bln rub | 87.2 | 71.6 | 75.8 | 75.9 | 71.3 | 294.6 | ||||
| R&D, bln rub | 7.90 | 6.80 | 6.10 | 6.80 | 7.00 | 26.7 | ||||
| Interest expenses, bln rub | 3.50 | 3.50 | 4.70 | 3.30 | 3.10 | 14.6 | ||||
| Assets, bln rub | 1 735 | 1 667 | 1 725 | 1 692 | 1 661 | 1 661 | ||||
| Net Assets, bln rub | ? | 1 299 | 1 235 | 1 222 | 1 236 | 1 228 | 1 228 | |||
| Debt, bln rub | 255.4 | 253.9 | 306.7 | 209.1 | 214.7 | 214.7 | ||||
| Cash, bln rub | 95.7 | 81.8 | 107.1 | 87.7 | 75.8 | 75.8 | ||||
| Net debt, bln rub | 159.7 | 172.1 | 199.6 | 121.4 | 138.9 | 138.9 | ||||
| Ordinary share price, rub | 29.7 | 25.6 | 20.2 | 22.4 | 19.9 | 21.5 | ||||
| Number of ordinary shares, mln | 46.6 | 46.8 | 46.8 | 46.2 | 46.2 | 46.2 | ||||
| Market cap, bln rub | 1 386 | 1 196 | 946 | 1 036 | 920 | 995 | ||||
| EV, bln rub | ? | 1 546 | 1 368 | 1 146 | 1 158 | 1 059 | 1 134 | |||
| Book value, bln rub | 233 | 250 | 188 | 201 | 200 | 200 | ||||
| EPS, rub | ? | -0.01 | -1.46 | -0.08 | 0.23 | -0.02 | -1.35 | |||
| FCF/share, rub | -0.23 | -0.14 | 0.54 | 0.15 | -0.26 | 0.29 | ||||
| BV/share, rub | 4.99 | 5.33 | 4.03 | 4.34 | 4.33 | 4.33 | ||||
| EBITDA margin, % | ? | 7.93% | 5.84% | 7.65% | 19.4% | 11.3% | 11.1% | |||
| Net margin, % | ? | -0.26% | -40.2% | -2.16% | 6.06% | -0.54% | -9.15% | |||
| FCF yield, % | ? | 4.62% | 2.88% | 3.87% | 1.41% | 1.45% | 1.34% | |||
| ROE, % | ? | 3.35% | -2.92% | -4.53% | -5.00% | -5.07% | -5.07% | |||
| ROA, % | ? | 2.51% | -2.16% | -3.21% | -3.65% | -3.74% | -3.74% | |||
| P/E | ? | 31.9 | -33.2 | -17.1 | -16.8 | -14.8 | -16.0 | |||
| P/FCF | 21.7 | 34.7 | 25.9 | 71.0 | 69.2 | 74.8 | ||||
| P/S | ? | 1.70 | 1.53 | 1.26 | 1.47 | 1.35 | 1.46 | |||
| P/BV | ? | 5.96 | 4.79 | 5.02 | 5.16 | 4.59 | 4.97 | |||
| EV/EBITDA | ? | 13.2 | 14.3 | 14.6 | 16.1 | 14.0 | 15.0 | |||
| Debt/EBITDA | 1.37 | 1.79 | 2.54 | 1.69 | 1.84 | 1.84 | ||||
| R&D/CAPEX, % | 197.5% | 170.0% | 156.4% | 115.3% | 170.7% | 149.2% | ||||
| CAPEX/Revenue, % | 2.09% | 2.36% | 2.28% | 3.40% | 2.47% | 2.63% | ||||
| Avanos Medical shareholders | ||||||||||
